

United States Patent and Trademark Office

UNITED STATES DEPAREMENT OF COMMERCE
United States Patent and Trademark Office
Address (CMMISSI-NERC) F PATENTS AND TRADEMARKS
Washington D = 20231
www.uspto.gov

APPLICATION NO	FILING DATE	FIRST NAMED INVENTOR	AITORNEY DOCKET NO.	CONFIRMATION NO		
09-734,613	12 13 2000	Marianne Bruggemann	37945-0009	3627		
	590 07 02 2002					
	John P. Isacson			EXAMINER		
Heller Ehrman White & McAuliffe LLP Suite 300 1666 K. Street, N.W.			WEHBE, ANNE MARIE SABRINA			
			ART UNIT	PAPER NUMBER		
Washington, DC 20006			1632	TATER NOMBER		
			DATE MAILED: 07:02/2002	10		

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICA	NT	ATTORNEY DOCKET NO.	
09/734,613	12/13/00	Bruggemann	37945-0009		
٢		٦			
				EXAMINER	
				A.M.S. Wehbé	
			ART UNIT	PAPER NUMBER	
			1632	10	
L		٦			
			DATE MAILED:		

Please find below a communication from the EXAMINER in charge of this application.

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821 (a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Specifically, the specification on page 20 contains sequences which are not identified by SEQ ID NOS.

Please note that while applicant's pre-amendment received on 5/2/01 attempted to amend the specification to include SEQ ID NOS for these sequences and further requested the insertion of the substitute sequence listing, this amendment does not comply with 37 CFR 1.121 and has not been entered. In particular, the amendment does not include a clean version of the replacement paragraph/section as required by 37 CFR 1.121 (b)(l)(ii), and/or does not include a marked-up version of the replacement paragraph/section 37 CFR 1.121 (b)(l)(iii). Resubmission of the amendment in the proper format (see the enclosed information flyer on simplified amendment practice) will place the application in compliance with 37 CFR 1.821-1.825.

Any inquiry concerning this communication should be directed to Examiner A.M.S. Wehbé, Ph.D., Art Unit 1632, whose telephone number is (703) 306-9156. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.

APPLICANT IS GIVEN A ONE MONTH EXTENDABLE PERIOD WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of this application under 37 CFR 1.821 (g). Extension of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice To Comply with the response.

Malai

Application No.: 09/734,613

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
X	7. Other: sequences on page 20 are not identified by SEQ ID NOS.,see attached letter
Аp	plicant Must Provide:
	An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For	questions regarding compliance to these requirements, please contact:
For	Rules Interpretation, call (703) 308-4216 CRF Submission Help, call (703) 308-4212 PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE